Generalized morphea after <scp>COVID</scp>‐19 vaccines: a case series

Paolino, Giovanni; Campochiaro, Corrado; Nicola, MR Di; Mercuri, SR; Rizzo, Nicola; Dagna, Lorenzo; Rongioletti, Franco; Luca, Giacomo De

doi:10.1111/jdv.18249

Cited by 15 publications

(13 citation statements)

References 10 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…136 Moreover, 40 cases of pemphigoids have been described. [137][138][139][140][141][142][143][144][145][146][147][148][149][150][151] Regarding other cutaneous diseases developed following COVID-19 vaccination, 9, 40, 55, 12 and 11 cases of morphea, [152][153][154][155][156][157] pityriasis rosea, [158][159][160][161][162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177] herpes zoster, [178][179][180][181][182][183][184]…”

Section: Resultsmentioning

confidence: 99%

“…Regarding other cutaneous diseases developed following COVID-19 vaccination, 9, 40, 55, 12 and 11 cases of morphea, 152–157 pityriasis rosea, 158–177 herpes zoster, 178–187 chilblains, 188–197 and vitligo 198–208 have been reported.…”

Section: Resultsmentioning

confidence: 99%

“… BNT162b2: 15 mRNA-1273: 6 AZD1222: 5 Ad26.COV2: 0 Pemphigoids 40 Maronese et al 137 (21), Maronese et al 138 (3), Hali et al 139 (3), Gambichler et al 140 (2), Shanshal et al 141 (1), Desai et al 142 (1), Fu et al 143 (1), Alshammari et al 144 (1), Hung et al 145 (1), Pauluzzi et al 146 (1), Dell’Antonia et al 147 (1), Pérez-López et al 148 (1), Agharbi et al 149 (1), Young et al 150 (1), Nakamura et al 151 (1). BNT162b2: 29 mRNA-1273: 5 AZD1222: 6 Ad26.COV2: 0 Morphea 9 Paolino et al 152 (4), Antoñanzas et al 153 (2), Oh et al 154 (1), Metin et al 155 (1), Aryanian et al 156 (1). BNT162b2: 6 mRNA-1273: 1 AZD1222: 2 Ad26.COV2: 0 Pityriasis rosea 40 Temiz et al 158 (14), Ramot et al 159 (6), Martora et al 160 (3), Khattab et al 161 (2), Cyrenne et al 162 (2), Valk et al 163 (1), Buckley et al 164 (1), Wang et al 165 (1), Shin et al 166 (1), Bostan et al 167 (1), Leerunyakul et al 168 (1), Cohen et al 169 (1), Dormann et al 170 (1), Bin Rubaian et al 171 (1), Fenner et al 172 (1), Marcantonio-Santa Cruz et al 173 (1...…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

“…Currently there are few reported cases in the literature of morphea secondary to COVID‐19 infection. 1 , 3 On the other hand, there are much fewer articles describing morphea secondary to COVID‐19 vaccines itself 6 , 7 , 8 , 9 , 10 (Table 1 ). Herein, we present one of the rare cases of new‐onset generalized morphea following COVID‐19 vaccine.…”

Section: Introductionmentioning

confidence: 99%

Generalized morphea following COVID‐19 vaccine: Case report and literature review

Alhayaza

Al-Garni

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“… 2 Contrariwise, there are very limited data regarding autoimmune skin diseases following SARS-CoV-2 vaccines 2 and there are only few reports of generalized morphea induced by COVID-19 mRNA vaccine. 4 …”

mentioning

confidence: 99%